Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax: 2022-2024

Historic Long-Term Deferred Tax for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $26.6 million.

  • Centessa Pharmaceuticals' Long-Term Deferred Tax fell 7.51% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year decrease of 7.51%. This contributed to the annual value of $26.6 million for FY2024, which is 10.32% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $26.6 million for FY2024, which was down 10.32% from $29.6 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $29.6 million for FY2023, and its period low was $3.5 million during FY2022.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $26.6 million (2024), whereas its average is $19.9 million.
  • In the last 5 years, Centessa Pharmaceuticals' Long-Term Deferred Tax soared by 744.16% in 2023 and then dropped by 10.32% in 2024.
  • Centessa Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $3.5 million in 2022, then spiked by 744.16% to $29.6 million in 2023, then fell by 10.32% to $26.6 million in 2024.